As of July 28, licensed opioid treatment programs (OTPs) can operate vans which dispense methadone. The final rule, issued June 28 by the Office of National Drug Control Policy (ONDCP), Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), follows the March 9, 2020 Notice of Proposed Rulemaking, making it clear that the … [Read more...] about DEA Okays Methadone Vans if Operated by OTPs
Emergency departments have long been able to give patients methadone to treat opioid use disorder (OUD) for three days. But there are problems with that: partly that patients have to keep coming back to get it every day, and, mainly, that doctors “just haven’t been excited about doing it,” in the words of Linda Hurley, president and CEO of CODAC Behavioral Healthcare. “We … [Read more...] about When emergency departments make referrals, are they sending them to treatment?
There are many bills and proposals which would loosen up treatment with methadone or buprenorphine. The better-known proposals to get rid of the X-waiver for buprenorphine are an important part of the story, but this story is specifically about making treatment in opioid treatment programs (OTPs) more convenient for patients. “Methadone reform” is a call to battle to many, … [Read more...] about Methadone treatment reform: A middle ground?
Krista Mayes, director of the addiction treatment provider program of NSM insurance, group, talked recently about the importance of prevention for opioid treatment programs (OTPs). Speaking at the April 10 Open Board meeting which ended the first day of the meeting of the American Association for the Treatment of Opioid Dependence (AATOD), Ms. Mayes focuses on keeping members … [Read more...] about NSM to AATOD Board: Be Proactive to Avoid Big Professional Liability Claims
The U.S. Food and Drug Administration has approved a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products. Naloxone is a medicine that can be administered by individuals with or … [Read more...] about FDA Approves Higher Dosage of Naloxone Nasal Spray